Method: Genetically modified probiotic Escherichia coli Nissle 1917 (EcN-20) producing a potent water soluble antioxidant pyrroloquinoline quinone (PQQ) was supplemented with oral citric acid and compared with another genetically modified probiotic EcN-21 producing PQQ and citric acid against oxidative stress induced by Cd and Hg. Rats were
To create a TAA-independent ProCAR platform, we engineered a well-characterized probiotic strain, Escherichia coli Nissle 1917 (EcN), which is equipped with a genomically integrated, synchronized lysis circuit (SLIC) for quorum-regulated delivery of synthetic CAR targets directly to the tumor core.
Of note, the probiotic strain E. coli Nissle 1917 (EcN) 112 has been safely used for nearly 100 years as the active pharmaceutical ingredient in multiple licensed medicinal products and the anti Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) with an increasing incidence in developed countries. Recent reports suggest that modulation of the gut microbiota might be one promising therapy for MS. Here, we investigated whether the probiotic Escherichia coli strain Nissle 1917 (ECN) could modulate the outcome of experimental autoimmune Ynyn.